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After allogeneic stem cell transplantation (allo-SCT), donor T cells may recognize minor histocompatibility
antigens (MiHA) speciﬁcally expressed on cells of the recipient. It has been hypothesized that Tcells recognizing
hematopoiesis-restricted MiHA mediate speciﬁc graft-versus-leukemia (GVL) activity without inducing graft-
versus-host disease (GVHD), whereas T cells recognizing ubiquitously expressed MiHA induce both GVL and
GVHD reactivity. It also has been hypothesized that alloreactive CD4 Tcells are capable ofmediating speciﬁc GVL
reactivity due to the hematopoiesis-restricted expression of HLA class II. However, clinical observations suggest
that an overt GVL response, associated with expansion of T cells speciﬁc for hematopoiesis-restricted antigens,
is often associated with GVHD reactivity. Therefore, we developed in vitro models to investigate whether
alloreactive T cells recognizing hematopoiesis-restricted antigens induce collateral damage to surrounding
nonhematopoietic tissues. We found that collateral damage to MiHA-negative ﬁbroblasts was induced by
misdirection of cytotoxic granules released from MiHA-speciﬁc T cells activated by MiHA-positive hemato-
poietic cells, resulting in granzyme-Bemediated activation of apoptosis in the surrounding ﬁbroblasts. We
demonstrated that direct contact between the activated T cell and the ﬁbroblast is a prerequisite for this
collateral damage to occur. Our data suggest that hematopoiesis-restricted Tcells actively participate in an overt
GVL response and may contribute to GVHD via induction of collateral damage to nonhematopoietic targets.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION skin explant models revealed modest (grade II) GVHD induc-
The graft-versus-leukemia/lymphoma (GVL) effect after
HLA-matched allogeneic stem cell transplantation (allo-
SCT) [1,2] mediated by donor T cells recognizing minor
histocompatibility antigens (MiHAs) [3-5] expressed on
malignant cells of the recipient is the major beneﬁcial
therapeutic effect of allo-SCT [2-8]. It has been hypothe-
sized that donor T cells recognizing MiHA expressed ubiq-
uitously on both hematopoietic and nonhematopoietic
tissues are involved in combined GVL and graft-versus-host
disease (GVHD) responses, whereas immune responses
directed against hematopoiesis-restricted MiHAs give rise
to speciﬁc GVL reactivity without coinciding GVHD.
Because HLA-DP is often not taken into account in the
donor search (10/10 HLA match), alloreactive donor T cells
directed against the mismatched HLA-DP allele(s) may
contribute to the GVL effect. Given that under normal condi-
tions, the expression of HLA class II is restricted to hemato-
poietic cells, it has been hypothesized that CD4 T cells are
capable of mediating a speciﬁc GVL effect without coinciding
GVHD [9-11]; however, mismatching for hematopoiesis-
restricted antigens, such as HA-1, in the allo-SCT setting has
been associated with a higher incidence of GVHD [12,13]. In
accordance with these clinical observations, in situ analysis of
the GVHD reactivity of HA-1e and HA-2especiﬁc T cells inedgments on page 769.
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14.03.002tion [14]. Moreover, we and others have observed that after
donor lymphocyte infusion (DLI), induction of a profound GVL
response accompanied by ampliﬁcation of T cell responses
against hematopoiesis-restricted antigens often coincides
with limited, mainly skin, GVHD.
Alloimmune responses after transplantation are unlikely
to be of single speciﬁcity, and thus the contribution of single
T cell responses cannot be precisely determined; nonetheless,
these observations may indicate a less stringent separation
between the tissue-speciﬁc expression of targeted antigens
and development of GVHD. We hypothesized that under
speciﬁc conditions, T cells directed against hematopoiesis-
restricted antigens may induce damage to nonhematopoietic
targets, possibly via the induction of collateral damage or
bystander lysis to nonhematopoietic cells, while targeting the
malignant/hematopoietic cells.
In 1986, using an in vitro model, Lanzavecchia et al.
[15] demonstrated that cytotoxic T lymphocytes (CTLs) trig-
gered by recognition of their speciﬁc target can kill other
cells that are not directly recognized by the T cells but are in
close contact with the triggered T cells. Furthermore, the
capacity of virus- and tumor-speciﬁc CD8/CD4 T cells to
induce collateral damage to neighboring bystander cells has
been demonstrated using in vitro models [16-18]. Conﬂicting
reports on the cytotoxic effector mechanisms underlying this
phenomenon have been published [15,16,19-25].
The aim of the present study was to investigate whether
and under what conditions T cells recognizing hematopoiesis-
restricted antigens (MiHAs or allo-HLA) may be able to induceTransplantation.
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to the GVHD response seen in profound GVL responses after
allo-SCTor DLI. To address this question, we developed in vitro
models mimicking the complex immunologic conditions after
allo-SCT. Our data suggest that under circumstances in which
themagnitude of the immune response dictates the formation
of a local proinﬂammatory environment leading to up-
regulation of adhesion molecules on the surrounding tissue
cells, hematopoiesis-restricted antigen-speciﬁc T cells can
interact with and, when simultaneously antigen-speciﬁcally
activated by hematopoietic (tumor) cells, damage the sur-
rounding nonhematopoietic cells. This phenomenon may
result in local development of GVHD or may amplify GVHD
reactivity during a profound GVL response without direct
antigen-speciﬁc recognition of the nonhematopoietic cells by
the T cells.
MATERIALS AND METHODS
Fibroblasts
After informed consent was provided, primary human ﬁbroblasts were
generated from skin biopsy specimens obtained from patients or healthy
donors. The skin biopsy specimens werewashed with PBS, minced, and then
transferred to 6-well culture plates containing low-glucose DMEM (Lonza,
Verviers, Belgium) supplemented with 10% FBS (Life Technologies, Breda,
The Netherlands). Fibroblasts were cultured to 90% conﬂuency and then
harvested using trypsin (Lonza) for 7minutes at 37 C, followed by 2washes.
Stock samples were cryopreserved in liquid nitrogen. After thawing, the
samples were reseeded at a concentration of 5000 cells/cm2 and recultured
to 90% conﬂuency, harvested, and reseeded. Experiments were performed
using ﬁbroblasts cultured for 5-20 passages. In speciﬁc experiments, ﬁbro-
blasts were pretreated for 2 days with IFN-g (200 IU/mL; Boehringer
Ingelheim, Alkmaar, The Netherlands). For speciﬁc experiments, ﬁbroblasts
were retrovirally transduced with pLZRS constructs encoding CD54, BCL-2,
PI9, c-FLIP, or empty vector (mock), linked to the truncated human nerve
growth factor receptor (NGFR) or green ﬂuorescent protein (GFP) selection
marker gene via an internal ribosome entry site (IRES) sequence [26-28].
The identity of all constructs was veriﬁed by sequencing. Retroviral super-
natants were generated with phoenix packaging (F-NX-A) cells, as
described previously [29], and used for transduction of ﬁbroblasts using
recombinant human ﬁbronectin fragments (CH-296; Lonza). Mock-, BCL-2e,
and PI-9-GFPetransduced ﬁbroblasts were puriﬁed by ﬂow cytometry cell
sorting, and mock-, CD54-, PI-9e, and c-FLIP-NGFRetransduced ﬁbroblasts
were stained with NGFR-PE and puriﬁed by magnetic-activated cell sorting
(MACS) using anti-PE beads (Miltenyi Biotec, Bergish Gladbach, Germany)
and/or ﬂow cytometry cell sorting.
Stimulator Cells
After informed consent was provided, peripheral blood samples were
obtained from healthy individuals, and peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll-isopaque separation and cryopreserved.
Stable Epstein-Barr virus (EBV)-transformed B cell lines (EBV-LCLs) were
generated as described previously and cultured in Iscove’s modiﬁed Dulbec-
co’s medium (IMDM; Lonza) supplemented with 10% FBS. Monocytes were
isolated from donor PBMCs by MACS isolation using magnetic CD14 Clin-
iMACS beads (Miltenyi Biotec) and then transformed into immature dendritic
cells (DCs) by culturing for 2 days at a concentration of 106 cells/mL in IMDM
containing 10% prescreened human serum supplemented with 100 ng/mL
granulocyte-macrophage colony stimulating factor (GM-CSF; Novartis, Basel,
Switzerland) and 500 IU/mL IL-4 (kindly provided by Schering-Plough,
Innishammon, Ireland), followed by 2 days of maturation using a cytokine
mixture containing 100 ng/mL GM-CSF, 10 ng/mL IL-1b (Cellgenix, Freiburg,
Germany),10 ng/mL IL-6 (Cellgenix), 10 ng/mLTNF-a (Boehringer Ingelheim),
500 IU/mL IFN-g (Immukine; Boehringer Ingelheim), and 1 mg/mL prosta-
glandin E2 (Sigma-Aldrich, Zwijndrecht, The Netherlands) to obtain mature
monocyte-derived DCs [30,31]. Acute lymphoblastic leukemia (ALL) cell lines
previously established in our laboratory from primary leukemic cells were
cultured in serum-free medium as described previously [32].
Generation and Culture of T Cell Clones and Primary T Cell Populations
The cytotoxic CD8þ T cell clone (CTL) RDR2, speciﬁc for the HLA-
A*0201erestricted MiHA LB-ADIR-1F, was previously isolated from periph-
eral blood of a patient at the time of clinical response to DLI as treatment for
relapsed multiple myeloma [33]. The HLA-A*0201erestricted SMCY311-319-
HYespeciﬁc CTL was isolated from a female patient after rejection of a male
stem cell graft [34]. The allo-HLA-A*0201especiﬁc CTL MBM13 was isolatedin vitro from an HLA-A*0201emismatched mixed lymphocyte reaction. The
HLA-A*0201erestricted HA-1especiﬁc CTL was isolated from a patient who
mounted a GVL response after allo-SCT with an HA-1enegative donor [35].
The CD4þ Tcell clones speciﬁc for HLA-DP2 or HLA-DP3were isolated from a
patient who mounted a GVL response after allo-SCT with an HLA-DPemis-
matched donor [36]. The T cell clones were expanded in expansion-medium
consisting of IMDM supplemented with 5% FBS, 5% prescreened pooled
human serum, and 100 IU/mL IL-2 (Chiron, Amsterdam, The Netherlands).
CTLs were restimulated using a feeder mixture containing expansion me-
dium supplemented with 5 irradiated (50 Gy) allogeneic PBMCs and
0.2 irradiated (50 Gy) allogeneic EBV-LCL, and 0.8 mg/mL phytohemag-
glutinin (PHA)-HA16 (Remel, Dartford, UK) every 3 weeks. T cells were used
for functional tests at 2-3 weeks after restimulation. Primary T cells were
obtained from donor PBMCs using the Pan T Cell Isolation Kit II (Miltenyi
Biotec), followed by positive selection of CD4- or CD8-naïve (CD45RAþ,
CD27þ) and memory (CD45ROþ) T cells by ﬂow cytometry.
Antibodies, Tetramers, and Flow Cytometry Analysis
The FITC-labeled mAbs against CD4, CD19, CD27, CD107a, and HLA-
A*0201; the PE-labeled mAbs against CD19, CD90, HLA-A*02, annexin V,
and NGFR; the cyanin dye 7ecoupled R-PE (PE-Cy7)-labeled mAb against
CD3; and the allophycocyanin-labeled mAbs against CD137 and CD8 were
obtained from BD Bioscience (San Jose, CA). CD90-FITC was obtained from
Beckman Coulter (Fullerton, CA). CD45RA-PE Texas redelabeled mAb was
obtained from Life Technologies. CD45RO-Alexa Fluor 700elabeled mAb
was obtained from ITK/Biolegend (Uithoorn, The Netherlands). Allophyco-
cyanin- or PE-labeled HLA-A*0201 tetramers containing the miHAs LB-
ADIR-1F, HA-1, and SMCY-HY were constructed as described previously [37].
For surface molecule staining, cells were labeled with mAbs for 30 mi-
nutes at 4C in PBS supplemented with 2% pasteurized plasma protein so-
lution (Sanquin, Amsterdam, The Netherlands). Identity of the CTL clones
was checked using surface staining with ﬂuorescent-labeled HLA-A*0201
tetramers containing the miHA peptide [37].
Analysis of T Cell Activation and Degranulation
T cell stimulation was performed by exposing 10,000 CTLs to different
T cell stimulators, including PHA 800 ng/mL, antieCD3-CD28 beads (T cell/
bead ratio 10/1; Dynabeads, Life Technologies), EBV-LCL, ALL, monocytes,
and immature and mature DCs (T cell/stimulator ratio 1/3). Supernatants
were harvested after 4 hours and 24 hours, and IFN-g release was measured
by standard ELISA (Sanquin). Granzyme-B release and perforin release were
measured in the same supernatants using human granzyme-B and perforin
ELISA kits (Abcam, Cambridge, MA). In speciﬁc experiments, target cells
were exogenously loaded with different concentrations (ranging from 1 pM
to 1 mM) of the relevant MiHA peptides (SVAPALALFPA;LB-ADIR-1F,
VLHDDLLEA;HA-1, or FIDSYICQV;SMCY-HY) for 1 hour at 37 C.
Analysis of T CelleMediated Cytotoxicity
For quantitative ﬂuorescence-activated cell sorting (FACS) analysis of
cytotoxicity [26], cells were taken up in 75 mL of PBS/2% pasteurized plasma
protein solution after surface Ab staining. Shortly before the FACS analysis,
10,000 Flow-Count beads (Beckman Coulter) and propidium iodide (PI)
were added. For each sample, 2000 beads were acquired. The numbers of
viable ﬁbroblasts were calculated by correcting the analyzed numbers of
CD90þ, PI cells for the number of beads. In speciﬁc experiments, cytotox-
icity was examined in the presence or absence of blocking anti-intercellular
adhesion molecule 1 (ICAM-1) mAbs (CD54, 5 ng/mL; ITK/Biolegend).
An annexin V apoptosis detection kit (BD Bioscience) was used for
apoptosis analysis. In brief, cells were resuspended in 50 mL of binding buffer
after surface Ab staining, after which annexin V-PE (1:50 dilution) and 2.5 mL
of 7AAD were added, followed by a 15-minute incubation at 4 C.
Confocal Microscopy
Primary human ﬁbroblasts (except for GFP-transduced ﬁbroblasts) were
labeled with 5 mM PKH67 according to manufacturer’s instructions (Sigma-
Aldrich) and seeded at 50,000 cells per glass bottom dish (P35G-1.5-14-C;
MatTek, Ashland, MA) and cultured in DMEMwithout phenol red (Lonza; Life
Technologies) supplemented with 10% FCS. After 3 days, medium was
removed, and the adherent cells were washed 3 times with IMDM without
phenol red (Lonza; Life Technologies) supplemented with 10% FCS. CTLs were
labeled with 5 mM PKH26 according to the manufacturer’s instructions
(Sigma-Aldrich), and added to the ﬁbroblasts at a 3/1 CTL/ﬁbroblast ratio in
IMDM without phenol red supplemented with 10% FCS and IL-2 (30 IU/mL).
Hematopoietic stimulator cells were labeled with 5 mM Claret Far Red Fluo-
rescent Cell Linker Kit (CellVue) according to the manufacturer’s instructions
(Sigma-Aldrich). PHA (800 ng/mL) or hematopoietic stimulator cells were
added to the cultures (CTL/stimulator ratio 1/3). The disheswere incubated for
different time intervals at 37C, followed by confocal microscopy analysis
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Heidelberg, Germany). Fibroblast viability was analyzed using red dead cell
staining (SYTOX; Life Technologies) according to the manufacturer’s in-
structions. SYTOX (1/100 dilution)was added 15minutes before visualization.
Images were analyzed using Leica confocal software and ImageJ.
Western Blot Analysis
For each sample, 107 cells were lysed in Triton lysis buffer as described
previously [27,28,38]. Equal amounts of cell lysates were separated on SDS-
PAGE gels, blotted onto PVDF membranes (Millipore, Bedford, MA), and
blocked with 5% BSA in PBS/Tween 0.05% (Sigma-Aldrich). Monoclonal
mouse anti-human Bcl-2 was purchased from Dako (Heverlee, Belgium;
clone 124), mouse anti-human PI-9 was purchased from Serotec (Duessel-
dorf, Germany; clone 7D8), and mouse anti-human b-actin (AC-15) was
purchased from Sigma-Aldrich. The mouse anti-human c-FLIP mAb NF6 was
a kind gift from P. H. Krammer (German Cancer Research Center, Heidelberg,
Germany) [39]. Goat anti-mouse IgG-biotin and Qdot 625-streptavidin were
used for detection (Life Technologies).
RESULTS
Activated MiHA-Speciﬁc T Cells Can Induce Collateral
Damage to Surrounding MiHA-Negative Fibroblasts
To investigate whether nonhematopoietic tissues that do
not express the relevant peptide/HLA complexes can beFigure 1. Activated alloreactive T cells can induce collateral damage to surrounding a
different MiHA- and allo-HLAespeciﬁc T cell clones (CTLs) was analyzed by quantita
CD8þ CTL clones directed against MiHA SMCY-HY and LB-ADIR-IF exerted direct cyto
MiHA-positive EBV-LCL ( ), but not against HLA-A*0201epositive, MiHA-negative ﬁ
cell:target cell ratio, 5:1). As expected, the CD8 clone recognizing the hematopoiesi
clones exerted cytotoxic activity only against MiHA/HLA-A*0201epositive and HLA-D
owing to a lack of expression of both HA-1 and class II on the ﬁbroblasts. Data shown
experiments. (B) No collateral damage to HLA-A*0201epositive, MiHA/HLA-DP2/3en
ADIR-1F, and HA-1) or HLA-DP2/3especiﬁc CD4 T cells (ﬁbroblast:T cell ratio, 1:5
MiHA/HLA-DP2/3enegative EBV-LCL (C) (T cell:EBV-LCL ratio, 1:3). Introduction of
collateral damage to the surrounding ﬁbroblasts ( ) (T cell:EBV-LCL ratio, 1:3). As a c
the absence of T cell clones. This did not result in lysis of the ﬁbroblasts ( ). Data s
pendent experiments. (C) Visualization of collateral damage induction to GFP-positiv
presence of CellVue-labeled (blue) MiHA-positive stimulator cells, but not in the absen
72 hours of coincubation (objective HC PL APO 20/0.700).targeted by the cytotoxic effect of antigen-speciﬁc T cells
during an ongoing response against antigen-positive he-
matopoietic target cells, we developed an in vitro model in
which HLA-A*0201epositive, MiHA-negative primary hu-
man ﬁbroblasts were exposed to CD8þ CTL clones speciﬁc for
different HLA-A*0201ebinding MiHA or CD4þ T cell clones
speciﬁc for HLA-DP, in the presence or absence of MiHA-
positive/HLA-DPepositive hematopoietic stimulator cells.
We ﬁrst examined the direct cytotoxic activity of the MiHA-
speciﬁc CTLs against the single targets and conﬁrmed that no
direct antigen-speciﬁc kill of MiHA-negative targets was
seen after 24 hours (Figure 1A). As control, it was demon-
strated that the CTLs speciﬁc for the ubiquitously expressed
MiHA LB-ADIR-1F and SMCY-HY showed efﬁcient lysis of
MiHA-positive ﬁbroblasts and EBV-LCL, demonstrating their
functional potency (Figure 1A). As expected, T cells targeting
the hematopoiesis-restricted MiHA HA-1 and the CD4þ T cell
clones targeting HLA-DP killed only the MiHA/HLA-
A*0201epositive or HLA-DPepositive EBV-LCL, respectively,
but not the ﬁbroblasts, owing to the lack of expression of
both HA-1 and HLA class II on the ﬁbroblasts.ntigen-negative ﬁbroblasts. Cytotoxicity against primary human ﬁbroblasts by
tive FACS analysis after 24 hours of coincubation. (A) HLA-A*0201erestricted
toxic activity against HLA-A*0201epositive, MiHA-positive ﬁbroblasts (C) and
broblasts (B) or HLA-A*0201epositive, MiHA-negative EBV-LCL ( ) (effector
s-restricted MiHA HA-1 and the HLA-DP2e and HLA-DP3especiﬁc CD4 T cell
P2/3epositive EBV-LCL, respectively ( ), and not against the ﬁbroblasts (C),
are mean  SD of 3 replicates from a representative of at least 3 independent
egative ﬁbroblasts was induced by MiHA-speciﬁc CD8þ T cells (SMCY-HY, LB-
) in the absence of third-party stimulator cells (B) and in the presence of
MiHA/HLA-DP2/3epositive EBV-LCL as third-party stimulator cells resulted in
ontrol, the MiHA/HLA-DP2/3epositive EBV-LCL were added to the ﬁbroblasts in
hown are mean  SD of 3 replicates from a representative of at least 3 inde-
e (green) ﬁbroblasts by PKH26-labeled (red) MiHA-speciﬁc CD8þ T cells in the
ce of stimulator cells or in the presence of MiHA-negative stimulator cells after
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activated by hematopoietic stimulator cells can induce
bystander lysis to surrounding nonhematopoietic cells, we
added MiHA-positive stimulator cells to the system as third-
party cells. Thus, MiHA-speciﬁc T cells seeded on a mono-
layer of MiHA-negative ﬁbroblasts were challenged with
MiHA-negative or MiHA-positive stimulator cells. MiHA-
speciﬁc CTLs and HLA-DP-speciﬁc CD4 T cells were capable
of inducing collateral damage to the surroundingMiHA/HLA-
DPenegative ﬁbroblasts only when stimulator cells
expressing the relevant HLA/MiHA complexes were added to
the system (Figure 1B). This phenomenon was conﬁrmed
by confocal ﬂuorescent microscopy visualization of loss of
GFP-labeled MiHA-negative ﬁbroblasts by PKH26-labeled
MiHA-speciﬁc CTLs in the presence of CellVue-labeled HLA-
A*0201/MiHA-positive stimulator cells, whereas no reduc-
tion in the number of viable ﬁbroblasts was observed in the
absence of third-party stimulator cells or after the addition of
MiHA-negative stimulator cells (Figure 1C). These data
indicate that induction of collateral damage to surrounding
MiHA-negative ﬁbroblasts is induced only after local T cell
activation.Figure 2. The strength of local T cell activation dictates the degree of collateral dam
monolayer of HLA-A*0201epositive, MiHA-negative ﬁbroblasts were activated usin
quantitative FACS analysis, and T cell activation was analyzed by IFN-g ELISA. (A) Acti
MiHA-negative ﬁbroblasts (CTL:ﬁbroblast ratio, 5:1) with different HLA-A*0201epo
ratio, 1:3) resulted in collateral damage to the surrounding ﬁbroblasts. As a control,
T cells. This did not result in ﬁbroblast lysis (B). Representative results are shown for t
CTLs. (B) Stimulation of the MiHA-speciﬁc T cells with MiHA-positive EBV-LCL, mature
stimulation with MiHA-positive monocytes did not. IFN-g production by the stimulato
are shown for the HA-1especiﬁc CTLs; similar results were obtained with other MiHA-
MiHA-negative ALL cells exogenously loaded with increasing concentrations of the M
dose-dependent activation, as reﬂected by IFN-g production. Representative results a
other MiHA-speciﬁc CTLs. (D) Stimulation of MiHA-speciﬁc CTLs seeded on a
A*0201epositive, MiHA-negative ALL cells loaded exogenously with increasing concen
cells resulted in dose-dependent lysis to the surrounding ﬁbroblasts. Representative
tained with other MiHA-speciﬁc CTLs.Strength of Local T Cell Activation by MiHA-Positive
Stimulator Cells Correlates with the Degree of Collateral
Damage to Surrounding MiHA-Negative Fibroblasts
We investigated whether collateral damage can be
induced when T cells are stimulated with other clinically
relevant targets using different primary hematopoietic
stimulator cells. Collateral damage to MiHA-negative ﬁbro-
blasts was induced by HLA-A*0201erestricted, MiHA-
speciﬁc CTLs on activation with HLA-A*0201/MiHA-positive
immature/mature monocyte-derived DCs and ALL cells to
the same degree as seen after stimulation with EBV-LCL.
Adding the stimulator cells to the ﬁbroblasts in the absence
of T cells did not induce collateral damage (Figure 2A).
Interestingly, stimulation with HLA-A*0201/MiHA-positive
monocytes resulted in only limited induction of collateral
damage.
Given that monocytes are known to be less potent
antigen-presenting cells (APCs), we examined the degree of
T cell activation after coincubation with the different targets
in the absence of ﬁbroblasts. Strong IFN-g production on
encountering all HLA-A*0201/MiHA-positive hematopoietic
targets was observed, with the exception of stimulationwithage to surrounding nonhematopoietic cells. MiHA-speciﬁc T cells seeded on a
g different stimulator cells. The resulting ﬁbroblast lysis was evaluated by
vation of MiHA-speciﬁc CTLs seeded on a monolayer of HLA-A*0201epositive,
sitive, MiHA-positive hematopoietic stimulator cells (C) (CTL:stimulator cell
the stimulator cells were added to the ﬁbroblast monolayer in the absence of
he HA-1especiﬁc CTLs; similar results were obtained with other MiHA-speciﬁc
and immature DCs, or ALL cells resulted in profound IFN-g production (C), but
r cells alone (without T cells) is shown as a control (B). Representative results
speciﬁc CTLs. (C) Stimulation of MiHA-speciﬁc CTLs with HLA-A*0201epositive,
iHA peptide or with HLA-A*0201epositive, MiHA-positive ALL cells resulted in
re shown for the LB-ADIR-1Fespeciﬁc CTLs. Similar results were obtained with
monolayer of HLA-A*0201epositive, MiHA-negative ﬁbroblasts with HLA-
trations of the MiHA peptide or with HLA-A*0201epositive, MiHA-positive ALL
results are shown for the LB-ADIR-1Fespeciﬁc CTLs; similar results were ob-
B. van der Zouwen et al. / Biol Blood Marrow Transplant 20 (2014) 760e769764monocytes (Figure 2B), which correlated with the observed
differential levels of coinciding collateral damage.
To investigate whether the strength of T cell activation
correlated with the degree of collateral damage, we used
HLA-A*0201epositive/MiHA-negative stimulator cells exog-
enously loaded with increasing concentrations of the rele-
vant MiHA peptide to stimulate MiHA-speciﬁc CTLs seeded
on a monolayer of MiHA-negative ﬁbroblasts. Dose-
dependent activation of the MiHA-speciﬁc CTL clone was
observed, as reﬂected by increasing levels of IFN-g produc-
tion (Figure 2C), and the amount of collateral damage to the
ﬁbroblasts showed a similar dose-dependent increase on
exogenous peptide loading of the stimulator cells
(Figure 2D). These data illustrate that the strength of local
activation of the T cells dictates the degree of collateral
damage to the surrounding ﬁbroblasts.
Collateral Damage Is Not Mediated via Cross-
Presentation of Peptide/HLA Complexes
Given the known ability of APCs to capture and present
exogenous peptides or even complete peptide/HLA com-
plexes from (dying) third-party cells [40-42], we investigatedFigure 3. Collateral damage is not mediated by cross-presentation of peptide/HLA com
complexes derived from MiHA-positive stimulator cells was the underlying mechanism
incubated MiHA-negative ﬁbroblasts either expressing or not expressing the HLA-A*0
with third-party stimulator cells or in a cell-free system. (A) HLA-A*0201erestricte
A*0201enegative (C) or HLA-A*0201epositive (B) ﬁbroblasts. Collateral damage to
CTLs with HLA-A*0201epositive, MiHA-positive EBV-LCL irrespective of the expres
seeded on a monolayer of MiHA-negative ﬁbroblasts using PHA in the absence of third
to the surrounding ﬁbroblasts, as seen after stimulation with third-party MiHA-positi
either PHA or the MiHA-positive EBV-LCL in the absence of CTLs (B). (C) Induction o
26elabeled MiHA-speciﬁc CTLs (red) on stimulation with PHA was visualized by confo
results are shown for the HA-1especiﬁc CTLs; similar results were obtained with thewhether the observed collateral damage to HLA-
A*0201epositive/MiHA-negative ﬁbroblasts was related to
cross-presentation of MiHA peptides released by the dying
MiHA-positive stimulator cells. We ﬁrst examined the effect
of expression of HLA-A*0201 by the ﬁbroblasts on the level
of collateral damage induced by HLA-A*0201erestricted
MiHA-speciﬁc CTLs. Similar levels of collateral damage
were induced in both HLA-A*0201epositive and HLA-
A*0201enegative MiHA-negative ﬁbroblasts. Moreover,
no collateral damage was observed when HLA-
A*0201enegative/MiHA-positive EBV-LCL were added to the
system as third-party stimulator cells (Figure 3A). These data
illustrate that cross-presentation of MiHA/HLA complexes
taken up from (dying) stimulator cells is not the dominant
mechanism underlying the induction of collateral damage to
the surrounding ﬁbroblasts.
To investigate the capability of CTLs to induce collateral
damage in a system inwhich cross-presentation is impossible,
we developed a model in which the MiHA-speciﬁc CTLs
seeded on a monolayer of ﬁbroblasts was activated in a cell-
free manner using T cell receptor (TCR) cross-linking by the
solubleactivatorPHA.Wedemonstrated that local stimulationplexes. To investigate whether cross-presentation of peptides or peptide/HLA
for collateral damage to MiHA-negative ﬁbroblasts by MiHA-speciﬁc CTLs, we
201 restriction molecule of the MiHA-speciﬁc CTLs, and then activated the CTLs
d MiHA-speciﬁc CTLs were seeded on a monolayer of MiHA-negative, HLA-
the surrounding ﬁbroblasts was induced on stimulation of the MiHA-speciﬁc
sion of HLA-A*0201 by the ﬁbroblasts. (B) Activation of MiHA-speciﬁc CTLs
-party stimulator cells resulted in similar levels of collateral damage induction
ve EBV-LCLs (C). No damage to the ﬁbroblasts was seen after incubation with
f collateral damage to MiHA-negative GFP-labeled ﬁbroblasts (green) by PKH-
cal microscopy (Hc PL APO CS 10/0.4 dry objective, 4 zoom). Representative
other MiHA-speciﬁc CTLs.
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cells resulted in very profound induction of collateral damage
to the surrounding MiHA-negative ﬁbroblasts, whereas the
addition of PHA in the absence of T cells did not affect the ﬁ-
broblasts (Figure 3B and C). This profound induction of
collateral damage to surrounding MiHA-negative ﬁbroblasts
on local stimulation of the CTLs in an activation model free of
third-party stimulator cells allowed us to analyze the under-
lying effector mechanisms in detail.
When Properly Activated, Primary Human T Cells
Can Induce Collateral Damage to Surrounding
Antigen-Negative Fibroblasts
Because the PHA stimulation model is not inﬂuenced by
the ﬁne speciﬁcity of the T cells, this model allowed us to use
polyclonal primary T cell populations instead of T cell clones.
CD8þ and CD4þmemory and naïve primary T cells were able
to induce collateral damage to surrounding ﬁbroblasts after
PHA stimulation. Importantly, no damage to the ﬁbroblasts
was induced by the primary T cell populations in the absence
of PHA, thus excluding the role of alloreactivity in these ex-
periments (Figure 4). These data further illustrate that on
profound local activation, any T cell can cause collateral
damage to surrounding nonhematopoietic cells.
Direct Contact between Activated T Cells and Fibroblasts
Is Required for Induction of Collateral Damage
To investigate whether collateral damage can be induced
when the T cells are in proximity to but not in direct contact
with the ﬁbroblasts, we ﬁrst analyzed whether soluble fac-
tors produced by the activated MiHA-speciﬁc T cells can
mediate the induction of collateral damage to the MiHA-
negative ﬁbroblasts. To do so, we exposed the ﬁbroblasts to
supernatants harvested from cocultures of MiHA-speciﬁc
CTLs and MiHA-positive stimulator cells. Although signiﬁ-
cant levels of secreted perforin and granzyme Bwere present
in the supernatants from CTLs stimulatedwith PHA or MiHA-
positive EBV-LCL, exposure to these supernatants did not
induce ﬁbroblast lysis. Separation of the activated T cells and
ﬁbroblasts in a Transwell system prevented the induction of
collateral damage, whereas in the positive control, coculture
of the 3 cell types in the same compartment resulted in in-
duction of collateral damage (Figure 5A and B). These dataFigure 4. Primary human T cells induce collateral damage to surrounding
nonhematopoietic cells on vigorous local activation. Selected populations of
naïve and memory CD8 and CD4 primary T cells were isolated from peripheral
blood of healthy donors and seeded on monolayers of human ﬁbroblasts
(T cell:ﬁbroblast ratio, 5:1). Whereas no direct (alloreactive) cytotoxicity was
induced against the ﬁbroblasts without stimulation of the T cells (B), clear
induction of ﬁbroblast lysis was observed after activation with PHA (C).
The antieSMCY-HY CD8 CTL clone served as a control.illustrate that profound activation of T cells in relative
proximity of the ﬁbroblasts does not lead to induction of
collateral damage to surrounding ﬁbroblasts.
To further investigate whether full cellecell contact is
necessary, we developed a model inwhich we could increase
and decrease the level of cellecell contact between the
activated T cells and the ﬁbroblasts. We added cell-sized
CD3/28 stimulation beads to nearly conﬂuent monolayers
of ﬁbroblasts and preattached Tcells. Whereas in the absence
of the CD3/28 beads, almost all CTLs were in close contact
with the ﬁbroblasts, adding the CD3/28 beads to the T cell/
ﬁbroblast monolayer resulted in attraction of the T cells and
signiﬁcantly reduced T celleﬁbroblast interaction, as re-
ﬂected in the decreased number of T cells showing red
ﬂuorescence at the ﬁbroblast level and the increased number
of T cells interacting with the beads showing red ﬂuores-
cence above the ﬁbroblast monolayer (Figure 5C). This CD3/
28-induced activation of the T cells in very close proximity to
the conﬂuent ﬁbroblast layer did not lead to induction of
collateral damage. In contrast, when all components (cells
and beads/PHA) were brought together in suspension,
allowing direct cellecell contact between the activated
T cells and the ﬁbroblasts, clear collateral damage was
observed, although the level of T cell activation as measured
by IFN-g production was similar in the 2 conditions
(Figure 5D and E).
Considering that ICAM-1 expression is known to be a key
factor in the interaction between T cells and ﬁbroblasts
[26,43,44], we investigated whether we could prevent
collateral damage induction by blocking T celleﬁbroblast
interaction using ICAM-1e blocking mAb. ICAM-1 blockade
signiﬁcantly decreased the level of collateral damage
(Figure 5F). These data illustrate that besides profound acti-
vation, direct cellecell contact between the activated T cells
and the ﬁbroblasts is critical for the induction of collateral
damage, and that this interaction is mediated, at least in part,
by ICAM-1.
Misdirection of Cytotoxic Granule Release Leads to
Induction of Collateral Damage via the Classical
Apoptotic Pathway
To investigate the exact effector mechanism responsible
for the induction of collateral damage, we studied the ki-
netics of ﬁbroblast death in more depth by staining with
SYTOX, a dye taken up solely by dead cells with disintegrated
membranes, and by annexin V staining as a marker for
apoptosis induction. Although morphological changes in the
ﬁbroblasts were already observed within 3 hours after local
T cell activation, no end-stage SYTOX-positive dead cells
were observed at that point. At 20 hours after local T cell
activation, all ﬁbroblasts had died, as demonstrated by their
complete disappearance and SYTOX staining of the remnants
(Figure 6A). Interestingly, within 3 hours after local T cell
stimulation, surrounding ﬁbroblasts showed positive
annexin V staining, demonstrating early initiation of the
apoptosis process, whereas no annexin Vepositive ﬁbro-
blasts were detected when ﬁbroblasts were cultured alone or
with unstimulated T cells (Figure 6B). These data illustrate
that although immediate initiation of the apoptosis process
in the ﬁbroblasts can be seen after local T cell activation, it
takes time before the ﬁbroblasts are truly dead, as demon-
strated by disintegration of their outer cell membranes.
To investigate whether we could identify the apoptotic
pathway responsible for collateral damage induction, we
increased the expression of inhibitors of the 3main apoptotic
Figure 5. Direct contact between the activated T cells and the ﬁbroblasts is required for the induction of collateral damage. To investigate the need for direct cellecell
contact between the activated T cells and the ﬁbroblasts for the induction of collateral damage, we activated the T cells in the neighborhood of or in close proximity of
the ﬁbroblasts without direct cellecell contact, or exposed the ﬁbroblasts to supernatants of activated T cells. (A) Supernatants of an MiHA-speciﬁc CTL clone
activated with PHA or with MiHA-positive EBV-LCL contained signiﬁcant amounts of granzyme B and perforin as detected on ELISA. (B) Exposure of the ﬁbroblasts to
supernatants of an MiHA-speciﬁc CTL clone stimulated with MiHA-positive ﬁbroblasts or separation of the MiHA-negative ﬁbroblasts (lower compartment) and the
coculture of MiHA-speciﬁc CTLs and MiHA-positive EBV-LCL (upper compartment) in a Transwell system did not result in collateral damage to the MiHA-negative
ﬁbroblasts. As a control, MiHA-negative ﬁbroblasts were cocultured with MiHA-speciﬁc CTLs and MiHA-positive EBV-LCL in the lower compartment of the Transwell
system. This resulted in signiﬁcant ﬁbroblast lysis. (C) PKH-26elabeled MiHA-speciﬁc CTLs (red) were seeded on a monolayer of PKH-67elabeled, CD54-transduced,
HLA-A*0201enegative, and MiHA-negative ﬁbroblasts (green) (CTL:ﬁbroblast ratio, 3:1), resulting in strong adherence of the T cells to the ﬁbroblasts after 1 hour of
coincubation, as shown by red ﬂuorescence at the ﬁbroblast level and a lack of red ﬂuorescence above the monolayer on confocal microscopy analysis. The addition of
T celleactivating CD3/28 microbeads resulted in capture of the T cells from the monolayer, as visualized by diminished red ﬂuorescence at the ﬁbroblast level and
increased red ﬂuorescence above the monolayer after 2 hours. This model was used for T cell activation in very close proximity to the ﬁbroblasts. (D) Either MiHA-
speciﬁc CTLs were seeded on a conﬂuent monolayer of MiHA-negative ﬁbroblasts before activation with PHA (B) or CD3/28 beads (C) (conﬂuent), or the CTLs,
ﬁbroblasts, and PHA/CD3/28 beads were added together in suspension, allowing direct cellecell contact (suspension). On PHA stimulation of the MiHA-speciﬁc CTLs,
collateral damage to the surrounding ﬁbroblasts clearly occurred under both conditions. In contrast, activation of the MiHA-speciﬁc CTLs with CD3/28 beads resulted
in induction of collateral damage only when direct cell contact between the T cells and the ﬁbroblasts was allowed (suspension), not when the T cells were captured
from the ﬁbroblast monolayer (conﬂuent) and were activated just above the ﬁbroblast monolayer. (E) Similar strength of T cell activation by PHA (B) and CD3/28
beads (C) was observed under both conditions (conﬂuent versus suspension) as measured by IFN-g ELISA. (F) Blockade of CTLeﬁbroblast interaction by the addition
of antieICAM-1 blocking antibodies abrogated the induction of collateral damage to the surrounding ﬁbroblasts on PHA stimulation (C). As a negative control, PHA
was added in the absence of CTLs (B).
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ceptor, granzyme Bemediated, and mitochondrial apoptosis
pathways, respectively, in the ﬁbroblasts by retroviral
transduction. Steady-state and induced c-FLIP, PI-9, and Bcl-2
protein expression in the ﬁbroblasts was demonstrated byWestern blot analysis (Figure 6C). Prevention of collateral
damage was not observed in ﬁbroblasts that had been
transduced with c-FLIP and Bcl-2, as demonstrated on an-
nexin V staining after coculturing with PHA-activated T cells.
In contrast, PI-9 overexpression resulted in clear protection
Figure 6. Induction of ﬁbroblast apoptosis by misdirection of cytotoxic granule release. The effector mechanism underlying the induction of collateral damage to ﬁ
broblasts by locally activated T cells was analyzed in different cell death assays. (A) PKH-26elabeled MiHA-speciﬁc CTLs (red) were seeded on a monolayer of FITC
labeled MiHA-negative ﬁbroblasts (green) and activated by the addition of PHA. The death cell staining dye SYTOX (blue) was added to stain end-stage dead cell
with a disintegrated cell membrane. Althoughmorphological changes in the ﬁbroblasts were observed as soon as 3 hours after Tcell stimulation by confocal ﬂuorescen
microscopy, true ﬁbroblast cell deathwas overt only after 20 hours. Theﬁbroblast cell remnants stained bluewith the SYTOX dye (HCX PL APO CS 40/1.25 oil objective)
(B) Apoptosis of GFP-labeled MiHA-negative ﬁbroblasts after coculture with PHA-stimulated MiHA-speciﬁc CTLs could be demonstrated after 3 hours by positive
stainingwith annexinV (red line). No annexin Vepositive ﬁbroblastswere detectedwithout CTLs (black line) and after coculturingwith CTLs in the absence of PHA (blue
line). The histograms are gated on GFP-positive cells. (C) Expression of the inhibitors of the main apoptosis pathways c-FLIP, PI-9, and Bcl-2 was increased by retrovira
transduction. Endogenous and up-regulated expression after transduction was evaluated by Western blot analysis. Lane 1 shows PI-9etransduced ﬁbroblasts, lane 2
shows c-FLIPetransduced ﬁbroblasts, lane 3 shows Bcl-2etransduced ﬁbroblasts, and lane 4 shows empty vector (mock)-transduced ﬁbroblasts. Stainingwith the Bcl-2
antibody was performed on the c-FLIPeprestained blot. Arrows indicate the speciﬁc bands. (D) Apoptosis of GFP-labeled ﬁbroblasts by PHA-stimulated T cells wa
observed in mock-, Bcl-2e, and c-FLIPetransduced ﬁbroblasts (blue lines). Apoptosis induction was prevented in PI-9etransduced ﬁbroblasts (red histograms) and by
the addition of EGTA (gray histograms). No induction of apoptosis was observedwithout CTLs or after coculturewith CTLs in the absence of PHA stimulation. Annexin V
staining gated on GFP-positive cells is shown after a 3-hour incubation. (E) Clear induction of ﬁbroblast cell death was observed in GFP-labeledmock-transducedMiHA
negative ﬁbroblasts (green) after 40 hours of coculturewith PHA-stimulated PKH-26elabeledMiHA-speciﬁc CTLs (red) as visualized by confocal microscopy (Hc PL APO
CS 10/0.4 dry objective, 4 zoom). Fibroblast lysis by PHA-stimulated CTLs was abrogated by overexpression of PI-9.
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of annexin Vepositive ﬁbroblasts (Figure 6D). This PI-9e
mediated protection against collateral damage was con-
ﬁrmed by visualizationwith confocal microscopy (Figure 6E).
Taken together, these data demonstrate that granzyme B
released from the CTL granules plays a key role in the in-
duction of collateral damage to surrounding nonhemato-
poietic cells.
To further demonstrate the role of cytotoxic granule
release by the activated T cells, we examined the effect of
inhibition of calcium-dependent degranulation by the addi-
tion of EGTA. Prevention of T cell degranulation by the
addition of EGTA to the coculture of ﬁbroblasts and PHA-
activated T cells abrogated the induction of collateral dam-
age (Figure 6D). Taken together, these data suggest that
collateral damage is induced by misdirection of cytotoxic
granules released by activated T cells, resulting in granzyme
Bemediated apoptosis induction in surrounding non-
hematopoietic cells when they are in direct contact with the
T cells.
DISCUSSION
The aim of the present study was to investigate whether
and, if so, under which conditions T cells recognizing MiHA
with a hematopoiesis-restricted expression pattern may be
able to induce damage to nonhematopoietic targets, thereby
contributing to the ampliﬁcation of a GVHD response that
often coincides with the induction of profound GVL re-
sponses after allo-SCT and DLI. We developed different
in vitro models to mimic the complex immunologic situation
after allo-SCT and to analyze in detail the interaction be-
tween antigen-speciﬁc T cells and nonhematopoietic pri-
mary human skinederived ﬁbroblasts that do not express
the antigens targeted by the T cells. We have demonstrated
that collateral damage to neighboring nonhematopoietic
cells could be induced by virtually every memory/naïve CD4/
CD8 T cell that is profoundly locally activated.
Induction of apoptosis via granzyme B released from the
activated T cells was the key mechanism, and stringent
adhesion between the T cell and the ﬁbroblast was a pre-
requisite for this collateral damage to occur. We found that
collateral damage was not induced by cross-presentation of
MiHA peptides or by peptide/MHC complexes taken up by
the ﬁbroblasts from dying MiHA-positive stimulator cells.
These data illustrate that along with antigen-speciﬁc direct
cytotoxicity by alloreactive T cells recognizing antigens
expressed on nonhematopoietic cells and ampliﬁcation of
the damage by the overwhelming cytokine storm coinciding
with this antigen-speciﬁc immune response [45], under
speciﬁc circumstances, damage to nonhematopoietic cells
also may occur through the induction of bystander lysis by
locally activated T cells.
Profound grade III-IV acute GVHD after allo-SCT is
thought to be caused by generalized damage induced by
alloreactive T cells massively inﬁltrating tissues and organs
and recognizing antigens expressed in these tissues and or-
gans, ampliﬁed by a cytokine storm accompanying the im-
mune response. Such generalized severe acute GVHD is
particularly prevalent after noneT celledepleted allo-SCT
using HLA-mismatched transplants. This is also the type of
GVHD that is nicely demonstrated in skin explant models
using male (HY)-speciﬁc T cells [14].
GVHD also can present in a more localized fashion,
however. Localized inﬁltration of T cells can lead to patchy
ﬁelds of inﬂammatory cells within a heterogeneous cellularcomposition in tissues. In contrast to generalized GVHD, the
extent of this local presentation of GVHD appears to be
somewhat controlled and thus is unlikely to be induced by
T cells recognizing antigens that are broadly expressed by all
nonhematopoietic cells. This form of local patchy modest
GVHD is frequently observed, especially in the more con-
trolled setting of T celledepleted allo-SCT. We hypothesize
that under these circumstances, the phenomenon of collat-
eral damage induction described in this article may play a
role. For instance, tissue-resident groups of patient-derived
hematopoietic APCs may result in local activation of patrol-
ling donor-derived T cells and induction of collateral damage
to neighboring nonhematopoietic cells. The extent of the
damage will depend on the absolute numbers/local prolif-
eration of patient-derived APCs and donor-derived T cells,
but the nature of and presentation of this form of GVHD
suggests that it is not caused by direct toxicity exerted by
alloreactive T cells recognizing antigens expressed on the
nonhematopoietic cells, but more likely is induced by a toxic
bystander lysis effect caused by locally activated T cells.
Given that the frequencies of potential alloreactive T cells are
dictated by the number of genetic differences between do-
nors and recipients, the use of unrelated donors likely will
increase the risk.
In essence, every Tcell, including virus- and tumor-speciﬁc
CD8/CD4 T cells, harbors the potential to induce collateral
damage to bystander cells, as demonstrated in different
in vitro models by us and others [15-25]. This property may
imply that collateral damage to nonhematopoietic cells can
occur evenwhen allo-SCT recipients are treated with selected
populations of donor T cells directed against antigens
expressed exclusively on (malignant) hematopoietic cells.
Although this is not likely to result in overtmassive damage as
is seen in acute GVHD after noneT celledepleted allo-SCT,
local induction of a profound hematopoiesis-speciﬁc im-
mune response may result in bystander lysis of neighboring
nonhematopoietic cells. This possibility ﬁts with the clinical
observations reported in patients with signiﬁcant levels of
malignant cells at the moment of onset of the GVL response,
when induction of a profound GVL response often coincides
with limited, local signs of GVHD, that mismatching for
hematopoiesis-restricted MiHAs like HA-1 in the allo-
transplantation setting is still associated with GVHD, as well
as with the signiﬁcant, albeit modest (grade II), GVHD reac-
tivity seen in skin explant models using HA-1e and HA-
2especiﬁc Tcells [12-14]. In the situation of local presentation
of virus infections in speciﬁc organs such as the gut or lungs
(cytomegalovirus disease), virus-speciﬁc T cells also may
cause local damage, not only via direct toxicity against virus-
infected cells, but also by ampliﬁcation of the damage via
the induction of collateral damage. Although ﬁbroblasts are
not generally assumed to be the primary target cell for acute
GVHD, ourﬁndings indicate that the susceptibility to collateral
damage is a common phenomenon in different nonhema-
topoietic target cell types. We were able to demonstrate
similar induction of collateral damage to in vitro cultures of
adherent tumor cell lines and keratinocytes (data not shown),
indicating that T cells may cause local damage in tissues and
organs via the mechanism of collateral damage.
In conclusion, our ﬁndings suggest that under speciﬁc
conditions, antigen-speciﬁc T cells may cause off-target
toxicity through induction of collateral damage to neigh-
boring antigen-negative cells. This toxicity may play a role in
the induction and/or ampliﬁcation of GVHD after allo-SCT
and DLI.
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